Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Appointed director
HALOZYME THERAPEUTICS, INC. (HALO) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/10/2022 8-K Quarterly results
02/22/2022 8-K Quarterly results
Docs: "HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS"
11/02/2021 8-K/A Quarterly results
Docs: "HALOZYME REPORTS THIRD QUARTER 2021 RESULTS"
11/02/2021 8-K Quarterly results
Docs: "HALOZYME REPORTS THIRD QUARTER 2021 RESULTS"
08/09/2021 8-K Quarterly results
Docs: "HALOZYME REPORTS SECOND QUARTER 2021 RESULTS"
05/10/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
11/02/2020 8-K Quarterly results
Docs: "HALOZYME REPORTS THIRD QUARTER 2020 RESULTS AND RAISES FULL YEAR 2020 GUIDANCE"
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
02/24/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "HALOZYME REPORTS FIRST QUARTER 2019 RESULTS"
02/21/2019 8-K Quarterly results
11/06/2018 8-K Quarterly results
Docs: "HALOZYME REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS"
08/07/2018 8-K Quarterly results
Docs: "HALOZYME REPORTS SECOND QUARTER 2018 RESULTS"
05/10/2018 8-K Quarterly results
Docs: "HALOZYME REPORTS FIRST QUARTER 2018 RESULTS"
11/07/2017 8-K Quarterly results
Docs: "HALOZYME REPORTS THIRD QUARTER 2017 RESULTS"
08/08/2017 8-K Quarterly results
Docs: "HALOZYME REPORTS SECOND QUARTER 2017 RESULTS"
05/09/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "HALOZYME REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS"
08/09/2016 8-K Quarterly results
Docs: "HALOZYME REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS - Revenue guidance raised to a range of $140 million to $150 million from prior range of $130 million to $145 million - - Strong progress in HALO-301 Phase 3 trial with site initiations in Europe, Asia Pacific and the United States - - ENHANZE™ platform momentum builds with launch of HYQVIA ® pediatric indication, European approval of Mabthera ® SC in chronic lymphocytic leukemia -"
05/09/2016 8-K Form 8-K - Current report
02/29/2016 8-K Quarterly results
Docs: "HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2015 FINANCIAL RESULTS"
11/09/2015 8-K Quarterly results
Docs: "HALOZYME REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS - Revenue of $20.8 million increased 42 percent from prior-year period - - Royalty Revenue of $8.3 million increased nearly 200 percent from prior-year period - - Company on track to close enrollment of PEGPH20 Phase 2 study in pancreatic cancer patients by year-end - SAN DIEGO, November 9, 2015 -- Halozyme Therapeutics, Inc. , a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the third quarter ended September 30, 2015. Revenue for the quarter of $20.8 million and a net loss of $24.5 million, or $0.19 per share, compared to revenue of $14.6 million and a net loss of $20.3 million, or $0.16 per share, for the third quarter of 2014. Financial results for the quarter were in..."
08/10/2015 8-K Quarterly results
Docs: "HALOZYME REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS - Record revenue of $43.4 million and net income of $3 million driven by $23 million initiation of AbbVie collaboration - - Revenue, expense and cash use guidance updated for 2015 - - First clinical collaboration for PEGPH20 signed with Eisai -"
05/11/2015 8-K Quarterly results
Docs: "HALOZYME REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS - Revenues increase 56 percent to $18.7 million, loss narrows to $15.1 million - - Royalty revenue increases 70 percent from the fourth quarter- - Interim results of Halozyme’s randomized Phase 2 study in pancreatic cancer to be presented at the annual meeting of the American Society of Clinical Oncology -"
03/02/2015 8-K Quarterly results
Docs: "HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS"
11/10/2014 8-K Quarterly results
Docs: "EXHIBIT"
08/11/2014 8-K Quarterly results
Docs: "HALOZYME REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS",
"HALOZYME REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS"
05/12/2014 8-K Quarterly results
Docs: "EX99.1"
02/27/2014 8-K Quarterly results
Docs: "EXHIBIT"
11/08/2013 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy